William Blair downgraded Enfusion (ENFN) to Market Perform from Outperform without a price target after the company announced an agreement to be acquired by Clearwater Analytics (CWAN) for $11.25 per share.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENFN:
- J&J to acquire Intra-Cellular, Clearwater to buy Enfusion: Morning Buzz
- Enfusion downgraded to Hold from Buy at Stifel
- Enfusion to Merge with Clearwater Analytics Holdings
- Clearwater Analytics to acquire Enfusion for $11.25 per share in cash, stock
- Enfusion price target raised to $11.50 from $10 at Piper Sandler